cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
== Diagnosis == A seroma may be diagnosed based on signs on the skin. On CT scans, seromas have a radiodensity of 0–20 Hounsfield units, generally in the lower part of this range, consistent with clear fluid.
=== Disruptions to agrifood systems === Agrifood systems are exposed to shocks and stresses of various types that differ in nature and intensity, including those impair agrifood systems by disrupting the operations of related institutions, supply chains and actors. Agrifood markets are operating in an era marked by recurrent, increasingly severe and overlapping shocks, including extreme weather events, conflicts, pandemics, financial crises, disease outbreaks, and sharp increases in energy and agricultural input prices. These shocks have disrupted production, trade flows and markets, exposing vulnerabilities across food supply chains. In a highly interconnected global economy, disruptions originating in one region can rapidly propagate across borders, affecting food availability, affordability and accessibility far beyond the location of the initial shock.
==== Adsorption and fusion ==== Sendai virus initiates infection process by host cell adsorption mediated by the recognition of specific receptor molecules. Hemagglutinin neuraminidase (HN) serves as a virus cell attachment protein that interacts with a specific cell entry receptor. NH has sialidase activity, and it is capable of cleaving sialic acid residues from the cell receptor. This cleavage triggers the fusion process of viral envelope and cell membrane, which promotes by cooperation of NH with the viral fusion protein (F). The SeV F-protein as other Paramyxovirus structural fusion proteins is a trimeric molecule that belongs to class I viral membrane fusion proteins. To perform the fusion function F protein must be proteolytically activated from it precursor inactive form F0. This activation requires F0 cleavage by host serine protease before the virus adsorption (see the section "proteolytic cleavage by cellular proteases"). F0 must be cleaved by the host protease into F1 and F2 subunits that remained connected through a disulfide covalent bond. The cleavage site in the F0-protein is located N-terminal to the fusion peptide which has N-terminal hepta-repeat 1 (HR1) and C-terminal Hepta-Repeat 2 (HR2) domains. The illustration below shows 5 stages of the fusion of the virus envelope and cellular host membrane. 1) The pre-fusion, F protein (highlighted in red) is protruding from the lipid bilayer of the viral envelope and is in a close proximity to the cellular membrane.
Sources: en.wikipedia.org
== Mechanical comminution == Mechanical comminution is the dominant family of techniques for industrial micronization. The process typically begins with coarse size reduction — crushing by hammer or impact mills and cutting by blade mills — which produces feed material in the millimetre-to-coarse-micrometre range from bulk solids. Conventional tumbling ball mills, in which a rotating drum loaded with steel or ceramic grinding media reduces the feed by impact and abrasion, are widely used for grinding in the 50–500 μm range but do not typically achieve micrometre-scale particle sizes on their own. True micronization to the 1–10 μm range is achieved by higher-energy mechanical techniques, principally jet milling for dry powders and wet bead milling or high-pressure homogenization for aqueous suspensions, which are described in the following sections. Industrial pharmaceutical micronization is dominated by mechanical comminution methods, particularly air-jet milling (also called fluid energy milling) and cryogenic milling. These mechanical methods scale from gram-level development batches to multi-metric-ton commercial campaigns and operate under current good manufacturing practice (cGMP) regulations such as 21 CFR Part 211 and ICH Q7. The choice of micronization technology depends on the active pharmaceutical ingredient's physical properties. Air-jet milling produces narrow, log-normal particle-size distributions typically with D50 below 5 µm and span ≤ 2, and is the standard approach for dry powder inhalation products and poorly soluble oral solids.
==== Non-B cell tumors ==== Hypoglycemia may occur in people with non-B cell tumors such as hepatomas, adrenocorticoid carcinomas, and carcinoid tumors. These tumors lead to a state of increased insulin, specifically increased insulin-like growth factor II, which decreases glucose levels.
=== Neuroprotection and DNA repair === Estrogen regulated DNA repair mechanisms in the brain have neuroprotective effects. Estrogen regulates the transcription of DNA base excision repair genes as well as the translocation of the base excision repair enzymes between different subcellular compartments. Estrogen provides neuroprotection by modulating the endocannabinoid system activity, primarily through the regulation of fatty acid amide hydrolase (FAAH) enzyme expression and the endocannabinoid receptor Cβ1 levels. The protective effects appears to work through a fine-tuning mechanism where by estrogen both suppresses excessive endocannabinoid signaling at the Cβ1receptor (which can be neurotoxic under stress) while simultaneously maintaining physiological endocannabinoid tine needed for normal neural function.
Sources: en.wikipedia.org
They present covalent cross-linkages between the polypeptide chains. These bonds are the strongest because they're covalent bonds, making them stronger than intermolecular forces. Glycosylation is another way to improve the thermostability of proteins. Stereoelectronic effects in stabilizing interactions between carbohydrate and protein can lead to the thermostabilization of the glycosylated protein. Cyclizing enzymes by covalently linking the N-terminus to the C-terminus has been applied to increase the thermostability of many enzymes. Intein cyclization and SpyTag/SpyCatcher cyclization have often been employed.
=== Ligand exchange/functionalization === After initial nanoparticle synthesis, colloidal gold ligands are often exchanged with new ligands designed for specific applications. For example, Au NPs produced via the Turkevich-style (or Citrate Reduction) method are readily reacted via ligand exchange reactions, due to the relatively weak binding between the carboxyl groups and the surfaces of the NPs. This ligand exchange can produce conjugation with a number of biomolecules from DNA to RNA to proteins to polymers (such as PEG) to increase biocompatibility and functionality. For example, ligands have been shown to enhance catalytic activity by mediating interactions between adsorbates and the active gold surfaces for specific oxygenation reactions. Ligand exchange can also be used to promote phase transfer of the colloidal particles. Ligand exchange is also possible with alkane thiol-arrested NPs produced from the Brust-type synthesis method, although higher temperatures are needed to promote the rate of the ligand detachment. An alternative method for further functionalization is achieved through the conjugation of the ligands with other molecules, though this method can cause the colloidal stability of the Au NPs to breakdown.
Pyrrole-2-carboxylate monooxygenase (EC 1.14.13.130, pyrrole-2-carboxylate oxygenase) is an enzyme with systematic name pyrrole-2-carboxylate,NADH:oxygen oxidoreductase (5-hydroxylating). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.